BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30810729)

  • 1. SOX8 acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer.
    Tang H; Chen B; Liu P; Xie X; He R; Zhang L; Huang X; Xiao X; Xie X
    Carcinogenesis; 2019 Oct; 40(10):1278-1287. PubMed ID: 30810729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZEB1 induced-upregulation of long noncoding RNA ZEB1-AS1 facilitates the progression of triple negative breast cancer by binding with ELAVL1 to maintain the stability of ZEB1 mRNA.
    Luo N; Zhang K; Li X; Hu Y
    J Cell Biochem; 2020 Oct; 121(10):4176-4187. PubMed ID: 31922280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular matrix marker LAMC2 targets ZEB1 to promote TNBC malignancy via up-regulating CD44/STAT3 signaling pathway.
    Wang D; Keyoumu K; Yu R; Wen D; Jiang H; Liu X; Di X; Zhang S
    Mol Med; 2024 May; 30(1):61. PubMed ID: 38760717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
    Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J
    Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1.
    Song W; Tang L; Xu Y; Sun Q; Yang F; Guan X
    J Exp Clin Cancer Res; 2017 Jun; 36(1):75. PubMed ID: 28583190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High SOX8 expression promotes tumor growth and predicts poor prognosis through GOLPH3 signaling in tongue squamous cell carcinoma.
    Chen S; Li H; Li X; Chen W; Zhang X; Yang Z; Chen Z; Chen J; Zhang Y; Shi D; Song M
    Cancer Med; 2020 Jun; 9(12):4274-4289. PubMed ID: 32307911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.
    Al-Marsoummi S; Vomhof-DeKrey E; Basson MD
    Cell Physiol Biochem; 2019; 53(6):999-1014. PubMed ID: 31838790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of cancerous progression by LISCH7 via direct stimulation of TGFB1 transcription in triple-negative breast cancer.
    Tang X; Zhou Y; Liu Y; Zhang W; Liu C; Yan C
    J Cell Biochem; 2020 Nov; 121(11):4642-4653. PubMed ID: 32048750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer.
    Wang PS; Chou CH; Lin CH; Yao YC; Cheng HC; Li HY; Chuang YC; Yang CN; Ger LP; Chen YC; Lin FC; Shen TL; Hsiao M; Lu PJ
    Oncogene; 2018 Aug; 37(34):4662-4678. PubMed ID: 29755127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer.
    Guo SJ; Zeng HX; Huang P; Wang S; Xie CH; Li SJ
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6379-6385. PubMed ID: 30338806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1.
    Damiano V; Brisotto G; Borgna S; di Gennaro A; Armellin M; Perin T; Guardascione M; Maestro R; Santarosa M
    Genes Chromosomes Cancer; 2017 Feb; 56(2):147-158. PubMed ID: 27717206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The deubiquitinase BRCC3 increases the stability of ZEB1 and promotes the proliferation and metastasis of triple-negative breast cancer cells.
    Huang Q; Zheng S; Gu H; Yang Z; Lu Y; Yu X; Guo G
    Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):564-575. PubMed ID: 38449391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
    Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
    Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic Regulation of
    Zhang H; Zhang N; Liu Y; Su P; Liang Y; Li Y; Wang X; Chen T; Song X; Sang Y; Duan Y; Zhang J; Wang L; Chen B; Zhao W; Guo H; Liu Z; Hu G; Yang Q
    Cancer Res; 2019 Jul; 79(13):3347-3359. PubMed ID: 30940661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT3 Targets
    Ma JH; Qi J; Lin SQ; Zhang CY; Liu FY; Xie WD; Li X
    Mol Cancer Res; 2019 Nov; 17(11):2184-2195. PubMed ID: 31427441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SALL4 promotes tumor progression in breast cancer by targeting EMT.
    Chen T; Tsang JYS; Su XC; Li P; Sun WQ; Wong ILK; Choy KY; Yang Q; Tse GMK; Chan TH; Chow LMC
    Mol Carcinog; 2020 Oct; 59(10):1209-1226. PubMed ID: 32835442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhophilin-associated tail protein 1 promotes migration and metastasis in triple negative breast cancer via activation of RhoA.
    Liu Q; Huang X; Li Q; He L; Li S; Chen X; Ouyang Y; Wang X; Lin C
    FASEB J; 2020 Aug; 34(8):9959-9971. PubMed ID: 32427399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
    Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
    Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.